Neoadjuvant and Adjuvant Sunitinib in Untreated Renal Cell Carcinoma
Sunitinib appears to be safe and effective when given before and after nephrectomy to previously untreated patients with metastatic renal cell carcinoma. Sarah Welsh, MD, of the Cancer Research UK Cambridge Institute, published the data from a single-arm phase II NeoSun trial in conjunction with the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract e16087).
In this study, patients scheduled for nephrectomy with no prior systemic therapy were recruited to receive 50 mg/day of sunitinib for 12 days. After surgery, patients moved to a 4-week on, 2-week off, repeating 6-week cycle until disease progression. A total of 14 patients received presurgery sunitinib, and 10 of those patients (71%) received all 12 planned doses. All 14 underwent total nephrectomy, and 13 resumed sunitinib postoperatively.
A confirmed response was achieved in 7 of 12 patients (58.3%), and 11 of 12 patients (91.7%) achieved an objective clinical benefit. No unexpected surgical or sunitinib-related toxicities or complications were observed, the investigators reported.